Skip to content
OpenCapital
Get started

BioLife Solutions BLFS AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02—

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%—
Operating margin-16.7%—
Net margin-68.7%—
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0×0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's afs and trading securities - unrealized loss position (<12 months) fair value.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's AFS and trading securities - unrealized loss position (<12 months) fair value?
BioLife Solutions (BLFS) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $57.93M in Q1 2026.
How has BioLife Solutions's AFS and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?
BioLife Solutions's AFS and trading securities - unrealized loss position (<12 months) fair value increased by 479.6% year-over-year, from $10M to $57.93M.